A Double Fail-Safe Approach to Prevent Tumorigenesis and Select Pancreatic β Cells from Human Embryonic Stem Cells
Mirza Muhammad Fahd Qadir1, Silvia Álvarez-Cubela2, Kinsley Belle2
1Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract:
The transplantation of human embryonic stem cell (hESC)-derived insulin-producing β cells for the treatment of diabetes is finally approaching the clinical stage. However, even with state-of-the-art differentiation protocols, a significant percentage of undefined non-endocrine cell types are still generated. Most importantly, there is the potential for carry-over of non-differentiated cell types that may produce teratomas. We sought to modify hESCs so that their differentiated progeny could be selectively devoid of tumorigenic cells and enriched for cells of the desired phenotype (in this case, β cells). Here we report the generation of a modified hESC line harboring two suicide gene cassettes, whose expression results in cell death in the presence of specific pro-drugs. We show the efficacy of this system at enriching for β cells and eliminating tumorigenic ones both in vitro and in vivo. Our approach is innovative inasmuch as it allows for the preservation of the desired cells while eliminating those with the potential to develop teratomas.
Insights
Scientists engineered human embryonic stem cells (hESCs) to eliminate potentially cancerous cells after differentiation. This advance improves the safety and purity of stem cell therapies for diabetes treatment.
Area of Science:
- Stem Cell Biology
- Regenerative Medicine
- Cancer Biology
Background:
- Human embryonic stem cell (hESC)-derived insulin-producing beta cells show promise for diabetes treatment.
- Current differentiation protocols generate non-endocrine cells and risk teratoma formation from undifferentiated hESCs.
Purpose of the Study:
- To engineer hESCs for selective elimination of tumorigenic cells and enrichment of beta cells.
- To develop a suicide gene system for enhanced safety in hESC-based therapies.
Main Methods:
- Generation of a modified hESC line with two suicide gene cassettes.
- Administration of specific pro-drugs to induce cell death in targeted cells.
- In vitro and in vivo validation of the system's efficacy.
Main Results:
- Demonstrated selective cell death of undifferentiated/tumorigenic cells upon pro-drug treatment.
- Achieved enrichment of insulin-producing beta cells post-differentiation.
- Confirmed safety and efficacy in both in vitro and in vivo models.
Conclusions:
- The developed suicide gene system effectively eliminates teratoma-forming cells while preserving desired beta cells.
- This approach enhances the safety profile of hESC-derived cell therapies for diabetes.
- Enables the generation of purer, safer cell populations for clinical transplantation.
Related Concept Videos
00:58Embryonic Stem Cells
00:57Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
01:13Induced Pluripotent Stem Cells
01:33Adult Stem Cells
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:17Hypothesis: Accept or Fail to Reject?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...